<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pralidoxime: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pralidoxime: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pralidoxime: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9802" href="/d/html/9802.html" rel="external">see "Pralidoxime: Drug information"</a> and <a class="drug drug_patient" data-topicid="10927" href="/d/html/10927.html" rel="external">see "Pralidoxime: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F212244"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Protopam Chloride</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061315"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Anticholinesterase</span>;</li>
<li>
<span class="list-set-name">Antidote, Organophosphate Poisoning</span></li></ul></div>
<div class="block don drugH1Div" id="F56565736"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1d65b67-0f84-4376-bafe-0f7732bed019">Organophosphate poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate poisoning (eg, pesticides, nerve agents): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<b>Note:</b></b> Must be used in conjunction with atropine; a response to atropine should be established before pralidoxime is administered. In older patients, the response to pralidoxime is highly variable and dependent on the organophosphate (some warfare and terrorism agents bind irreversibly within minutes), the length of time since the exposure, body mass index, and the toxic dose (Lee 2014; Moon 2015). Reported experience in neonatal patients is sparse and dosing based on case reports and expert recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonate: IV: 20 to 50 mg/kg as a single dose (AAP [Shenoi 2020]); reported dose range: 23 to 30 mg/kg and treatment PNA range: 0 to 25 days; in one case report, doses were repeated for recurrent symptom episodes; data in premature neonates is lacking (AAP [Shenoi 2020]; Das 2019; Jajoo 2010; Kaur 1996). <b>Note:</b> In older pediatric patients, a continuous IV infusion at 10 to 20 mg/kg/hour is recommended for maintenance dosing (see "Dosing: Pediatric"); although there is no neonatal experience reported with a continuous IV infusion, it may be recommended by some experts (AAP [Shenoi 2020]). Consultation with a poison control center or clinical toxicologist is highly recommended to determine optimal care.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F212258"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4375431e-bfd0-4b44-a9df-84d6db321673">Anticholinesterase overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticholinesterase overdose (eg, neostigmine, pyridostigmine):</b> Very limited data available: Children and Adolescents: IV: 30 mg/kg/dose for 2 doses; dosing based on a case report describing rivastigmine poisoning in a 3-year-old who received atropine and 2 doses of pralidoxime (administered at 5 hours and 6 hours postingestion); after second dose, clinical symptoms improved and an increase in plasma acetylcholinesterase activity was observed (Saz 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1d65b67-0f84-4376-bafe-0f7732bed019">Organophosphate poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate poisoning (eg, pesticides, nerve agents): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Must be used in conjunction with atropine; a response to atropine should be established before pralidoxime is administered. A combination product containing both pralidoxime and atropine is available as an autoinjector kit (eg, DuoDote) for use in patients weighing &gt;41 kg. The response to pralidoxime is highly variable and is dependent on the organophosphate (some warfare and terrorism agents bind irreversibly within minutes), the length of time since the exposure, body mass index, and the toxic dose (Lee 2014; Moon 2015); the optimal dosing regimen for pralidoxime has not been established (WHO 2006). Administration via IM or SUBQ routes should be considered when IV administration is not feasible.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Loading dose:</i> IV: 20 to 50 mg/kg; maximum dose: 2,000 mg/dose (AAP [Shenoi 2020]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance dosing</i>: <b>Note:</b> In patients with severe intoxication, maintenance treatment should be administered as a continuous infusion when possible (WHO 2006). The duration of therapy based on clinical status of the patient; severe intoxication may result in prolonged redistribution of the organophosphate.</p>
<p style="text-indent:-2em;margin-left:10em;">Continuous IV Infusion: 10 to 20 mg/kg/hour not to exceed 500 mg/hour (AAP [Shenoi 2020]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent IV: 20 to 50 mg/kg; maximum dose: 2,000 mg/dose; may be repeated after 1 hour if muscle weakness has not been relieved; then may repeat every 10 to 12 hours as needed (per the manufacturer); however, more frequent dosing of 4 to 6 hours as needed has been recommended (WHO 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Loading dose: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Weight-directed dosing: IV: 30 mg/kg; maximum dose: 2,000 mg/dose (Howland 2018; Roberts 2007).</p>
<p style="text-indent:-2em;margin-left:10em;">Fixed dosing: IV: 2,000 mg (WHO 2006). <b>Note:</b> A lower fixed dose of 1,000 mg is recommended by the manufacturer; however, this regimen may result in sub-therapeutic concentrations (WHO 2006).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance dose:</i>
<b>Note:</b> In patients with severe intoxication, maintenance treatment should be administered as a continuous infusion when possible (WHO 2006).The duration of therapy based on clinical status of the patient; severe intoxication may result in prolonged redistribution of the organophosphate.</p>
<p style="text-indent:-2em;margin-left:10em;">Continuous IV Infusion:</p>
<p style="text-indent:-2em;margin-left:12em;">Weight-directed dosing: 8 to 10 mg/kg/hour, not to exceed a maximum of 650 mg/hour as a continuous IV infusion (Howland 2018; Roberts 2007).</p>
<p style="text-indent:-2em;margin-left:12em;">Fixed dosing: 500 mg/hour (WHO 2006).</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent IV: 1,000 to 2,000 mg administered 1 hour after loading dose if muscle weakness has not been relieved; repeat every 10 to 12 hours as needed (per the manufacturer); however, more frequent dosing of 4 to 6 hours as needed has been recommended (WHO 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">IM, SUBQ: <b>Note:</b> If IV administration not feasible, the IM route is preferred over subcutaneous.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;40 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild symptoms:</i> IM, SUBQ: 15 mg/kg/dose; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 45 mg/kg; may administer doses in rapid succession if severe symptoms develop.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe symptoms:</i> IM, SUBQ: 15 mg/kg/dose; repeat twice in rapid succession to deliver a total dose of 45 mg/kg (total).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Persistent symptoms:</i> IM, SUBQ: If symptoms persist after a complete 3-dose course, may repeat the entire series (45 mg/kg in 3 divided doses) beginning ~1 hour after administration of the last injection.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents ≥40 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild symptoms:</i> IM, SUBQ: 600 mg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 1,800 mg; may administer doses in rapid succession if severe symptoms develop.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe symptoms:</i> IM, SUBQ: 600 mg; repeat twice in rapid succession to deliver a total dose of 1,800 mg (total).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Persistent symptoms:</i> IM, SUBQ: If symptoms persist after a complete 3-dose course, may repeat the entire series (1,800 mg in 3 divided doses) beginning ~1 hour after administration of the last injection.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51154222"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, because pralidoxime is excreted in the urine, dosage reduction is recommended in patients with renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51154223"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F212248"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9802" href="/d/html/9802.html" rel="external">see "Pralidoxime: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4375431e-bfd0-4b44-a9df-84d6db321673">Anticholinesterase overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticholinesterase overdose (eg, neostigmine, pyridostigmine):</b>
<b>IV:</b> 1,000 to 2,000 mg; followed by increments of 250 mg every 5 minutes as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1d65b67-0f84-4376-bafe-0f7732bed019">Organophosphate poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate poisoning (eg, pesticides and nerve agents):</b>
<b>Note:</b> Must be used in conjunction with atropine; a response to atropine should be established before pralidoxime is administered. A combination product containing both pralidoxime and atropine is available as an auto-injector kit (eg, Duodote) which is used most often by civilian first responders or by military personnel for self-injected or buddy administration. The response to pralidoxime is highly variable and is dependent on the organophosphate, the length of time since the exposure, and the toxic dose (Lee 2014; Moon 2015); the optimal dosing regimen for pralidoxime has not been established (WHO 2006). IM or SUBQ administration should be considered when IV administration is not feasible:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b>
<b>Note: </b>In patients with severe intoxication, maintenance treatment should be administered as a continuous infusion when possible (WHO 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 30 mg/kg (maximum: 2,000 mg) (Howland 2018; Roberts 2007) <b>or </b>2,000 mg (WHO 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Continuous infusion (preferred): </i>8 to 10 mg/kg/hour (maximum: 650 mg/hour) (Howland 2018; Roberts 2007) <b>or </b>500 mg/hour (WHO 2006); severe intoxication may result in prolonged redistribution of the organophosphate; the duration of therapy should reflect the clinical status of the patient.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Intermittent infusion: </i>May repeat loading dose after 1 to 2 hours if muscle weakness has not been relieved, followed by repeated dosing every 4 to 6 hours as needed (WHO 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (preferred), SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild symptoms:</i> 600 mg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 1,800 mg; may administer doses in rapid succession if severe symptoms develop.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe symptoms:</i> 600 mg; repeat twice in rapid succession to deliver a total dose of 1,800 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Persistent symptoms:</i> May repeat the entire series (1,800 mg) beginning ~1 hour after administration of the last injection.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991185"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, because pralidoxime is excreted in the urine, dosage reduction is recommended in patients with renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50988490"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; undergoes hepatic metabolism.</p></div>
<div class="block adr drugH1Div" id="F212216"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrest, hypertension, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Dizziness, drowsiness, headache, paralysis, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Maculopapular rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Increased serum ALT (transient), increased serum AST (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site (IM)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Fasciculations, increased creatine phosphokinase, laryngospasm, muscle rigidity, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Abnormal accommodation, blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Apnea, hyperventilation</p></div>
<div class="block coi drugH1Div" id="F212231"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no absolute contraindications listed within the manufacturer’s labeling. <b>Note:</b> According to the manufacturer, relative contraindications include hypersensitivity to pralidoxime or any component of the formulation and other situations where the risk of administration clearly outweighs possible benefit.</p></div>
<div class="block war drugH1Div" id="F212214"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carbamate poisoning: Pralidoxime is <b>not</b> indicated for the treatment of carbamate poisoning (WHO 2006); acetylcholinesterase is weakly, but not permanently, affected by carbamates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; administration may precipitate a myasthenic crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nonanticholinesterase poisoning: Pralidoxime is <b>not</b> indicated for the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates without anticholinesterase activity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage modification required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Clinical symptoms that are consistent with suspected organophosphate poisoning (eg, organophosphate anticholinesterase pesticides and nerve agents) should be treated with the antidote immediately; administration should not be delayed for confirmatory laboratory tests. Treatment should include proper evacuation and decontamination procedures as indicated; medical personnel should protect themselves from inadvertent contamination. Antidote administration is intended only for initial management; definitive and more intensive medical care is required following administration. Individuals should not rely solely on antidote for treatment; the concomitant use of atropine will be necessary and other supportive measures (eg, artificial respiration) may still be required.</p></div>
<div class="block foc drugH1Div" id="F212224"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Intramuscular, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mg/2 mL (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Protopam Chloride: 1 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F212210"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323722"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Protopam Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $104.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613637"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Use a 300 mg/mL solution; either autoinjector or reconstituted powder for injection may be used; in infants and children, administer intramuscularly in the anterolateral aspect of the thigh.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>Note:</b> Rapid IV infusion may be associated with temporary worsening of cholinergic manifestations (eg, tachycardia, laryngospasm, muscle rigidity, cardiac arrest) in adults; in children, muscle fasciculations, apnea, and convulsions have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Infuse over 15 to 30 minutes; if maximally concentrated solution (50 mg/mL) may be administered over ≥5 minutes not to exceed 200 mg/minute. Some experts recommend slower administration over 30 to 60 minutes (AAP [Shenoi 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose (intermittent infusion): Infuse over 15 to 30 minutes a rate not to exceed 200 mg/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: May administer SUBQ if IM or IV administration is not feasible.</p></div>
<div class="block adm drugH1Div" id="F212228"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Infuse as a 10 to 20 mg/mL solution over 15 to 30 minutes. Alternatively, if this is not practical or if pulmonary edema is present and/or fluid restriction is necessary, may administer as a 50 mg/mL solution by slow IV injection over ≥5 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: Administer as a continuous or intermittent infusion at a rate not to exceed 200 mg/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM, SUBQ:</b> May administer IM (preferred) or SUBQ if IV administration is not feasible. If using the auto-injector (solution for IM injection) for IM administration, remove gray safety cap and place black end against outer thigh. Push hard until injector administers, hold in place for 10 seconds, then remove and massage area of injection. Auto-injector is intended for use by military personnel for self or buddy administration; may also be administered by qualified civilian emergency responders who have received adequate training on the recognition and treatment of nerve agent intoxication.</p></div>
<div class="block sts drugH1Div" id="F212240"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 7 to 18 g be stocked. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period; actual amount to be stocked should take into account site-specific and population-specific needs. Hospitals serving agricultural regions where organophosphate insecticides are used should ensure that they maintain adequate supplies (Dart 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Mass casualty event secondary to an acetylcholinesterase inhibitor: In the unlikely occurrence of a mass casualty event secondary to an acetylcholinesterase inhibitor, supplies of pralidoxime may rapidly deplete, including predeployed CHEMPACK containers. Both the US Food and Drug Administration (FDA) and the American College of Medical Toxicology (ACMT) recommend the use of expired medications, including auto-injectors, if needed in this situation (ACMT [Stolbach 2018]; FDA 2021).</p></div>
<div class="block usep drugH1Div" id="F53568460"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and terrorism nerve agents (FDA approved in pediatric patients [age not specified] and adults); control of overdose of anticholinesterase medications used to treat myasthenia gravis (eg, ambenonium, neostigmine, pyridostigmine) (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> To be used in conjunction with atropine (Howland 2018); the role of oximes in organophosphate poisoning remains unclear and efficacy is dependent on the organophosphate ingested, the length of time since the exposure, body mass index, and the toxic dose (Eddleston 2018; Lee 2014; Moon 2015). The overall impact of oximes on patient outcomes has been questioned (Blumenberg 2018).</p></div>
<div class="block mst drugH1Div" id="F212271"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pralidoxime may be confused with pramoxine, pyridoxine</p>
<p style="text-indent:-2em;margin-left:4em;">Protopam may be confused with protamine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299930"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F212218"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13459587"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. A case report did not show evidence of adverse events after pralidoxime administration during the second trimester (Kamha 2005). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>
<div class="block mopp drugH1Div" id="F53568437"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, respiratory rate, muscle fasciculations and strength, pulse oximetry, blood pressure and cardiac monitoring with IV administration.</p></div>
<div class="block pha drugH1Div" id="F212213"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reactivates cholinesterase that had been inactivated by phosphorylation due to exposure to organophosphate pesticides and cholinesterase-inhibiting nerve agents (eg, terrorism and chemical warfare agents such as sarin) by displacing the enzyme from its receptor sites; removes the phosphoryl group from the active site of the inactivated enzyme </p></div>
<div class="block phk drugH1Div" id="F212230"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>dss</sub>: 0.6 to 2.7 L/kg; Severely poisoned pediatric patients (n=11; age: 0.8 to 18 years): ~9 L/kg (range: 1.7 to 13.8 L/kg) (Schexnayder 1998); may increase with increasing severity of organophosphate intoxication </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: None </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Apparent: 74 to 77 minutes; Poisoned patients (IM, IV): 3 to 4 hours; Pediatric patients (n=11; age: 0.8 to 18 years): 2.4 to 5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: IV: 5 to 15 minutes; IM: ~35 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (80% as metabolites and unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51219417"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Decreased renal function will result in increased blood levels of pralidoxime.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038776"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Pradox | Pralidox</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Pralidoxime</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Protopam chloride</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cbc pam | Clopam | Lyphe</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Pam</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Newpudox | Pam-a | Pamu</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Neopam</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Protopam</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Protopam chloride</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Neopam | Pralidoxime chloride 2 pam asian pharm</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Contrathion</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Pam | Pamcl | Pampara</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Agency for Toxic Substances and Disease Registry (ATSDR). Medical Management Guidelines for Nerve Agents: Tabun (GA); Sarin (GB); Soman (GD); and VX. August 2008. <a href="https://www.atsdr.cdc.gov/mhmi/mmg166.pdf" target="_blank">http://www.atsdr.cdc.gov/mhmi/mmg166.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29230717">
<a name="29230717"></a>Blumenberg A, Benabbas R, deSouza IS, et al. Utility of 2-pyridine aldoxime methyl chloride (2-PAM) for acute organophosphate poisoning: a systematic review and meta-analysis. <i>J Med Toxicol</i>. 2018;14(1):91-98. doi:10.1007/s13181-017-0636-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/29230717/pubmed" id="29230717" target="_blank">29230717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31086169">
<a name="31086169"></a>Das JC, Hasan SH, Sharmin T, et al. Organophosphorus compounds poisoning in a neonate: a case report. <i>Mymensingh Med J</i>. 2019;28(2):470-473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/31086169/pubmed" id="31086169" target="_blank">31086169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3418775">
<a name="3418775"></a>de Kort WL, Kiestra SH, and Sangster B. The use of atropine and oximes in organophosphate poisoning: a modified approach. <i>J Toxicol Clin Toxicol</i>. 1988;26(3-4):199-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/3418775/pubmed" id="3418775" target="_blank">3418775</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Eddleston M. Insecticides: Organic phosphorus compounds and carbamates. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2018:1486-1502.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7941519">
<a name="7941519"></a>Ekins BR, Geller RJ. Methomyl-induced carbamate poisoning treated with pralidoxime chloride. <i>West J Med</i>. 1994;161(1):68-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/7941519/pubmed" id="7941519" target="_blank">7941519</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Howland MA. Antidotes in Depth: Pralidoxime. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2018:1503-1507.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20522300">
<a name="20522300"></a>Jajoo M, Saxena S, Pandey M. Transplacentally acquired organophosphorus poisoning in a newborn: case report. <i>Ann Trop Paediatr</i>. 2010;30(2):137-139. doi:10.1179/146532810X12703902516202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/20522300/pubmed" id="20522300" target="_blank">20522300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2818204">
<a name="2818204"></a>Jovanovic D. Pharmacokinetics of pralidoxime chloride. A comparative study in healthy volunteers and in organophosphorus poisoning. <i>Arch Toxicol</i>. 1989;63(5):416-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/2818204/pubmed" id="2818204" target="_blank">2818204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15853933">
<a name="15853933"></a>Kamha AA, Al Omary IY, Zalabany HA, et al. Organophosphate poisoning in pregnancy: a case report. <i>Basic Clin Pharmacol Toxicol</i>. 2005;96(5):397-398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/15853933/pubmed" id="15853933" target="_blank">15853933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9019442">
<a name="9019442"></a>Kaur I, Jayashree K, Hiranandani M, Singhi SC. Severe organophosphate poisoning in a neonate. <i>Indian Pediatr</i>. 1996;33(6):517-519.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/9019442/pubmed" id="9019442" target="_blank">9019442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2403479">
<a name="2403479"></a>Kurtz PH. Pralidoxime in the treatment of carbamate intoxication. <i>Am J Emerg Med</i>. 1990;8(1):68-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/2403479/pubmed" id="2403479" target="_blank">2403479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24856742">
<a name="24856742"></a>Lee DH, Jung KY, Choi YH, Cheon YJ. Body mass index as a prognostic factor in organophosphate-poisoned patients. <i>Am J Emerg Med</i>. 2014;32(7):693-696. doi:10.1016/j.ajem.2014.04.030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/24856742/pubmed" id="24856742" target="_blank">24856742</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Medicis JJ, Stork CM, Hoffman RS, et al. Improved 2-PAM dosing regimen in human volunteers: a pharmacokinetic study. <i>Vet Hum Toxicol</i>. 1994;36:377.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al. Adult toxicology in critical care: part II: specific poisonings. <i>Chest</i>. 2003;123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25712411">
<a name="25712411"></a>Moon J, Chun B, Lee S. Variable response of cholinesterase activities following human exposure to different types of organophosphates. <i>Hum Exp Toxicol</i>. 2015;34(7):698-706. doi:10.1177/0960327114558890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/25712411/pubmed" id="25712411" target="_blank">25712411</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Murphy M, Desai H. Pralidoxime-Induced Laryngospasm. <i>Vet Hum Toxicol</i>. 1994;36:375.</div>
</li>
<li>
<div class="reference">
                  Protopam (pralidoxime) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17379909">
<a name="17379909"></a>Roberts DM, Aaron CK. Management of acute organophosphorus pesticide poisoning. <i>BMJ</i>. 2007;334(7594):629-634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/17379909/pubmed" id="17379909" target="_blank">17379909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28328690">
<a name="28328690"></a>Saz EU, Yurtseven A, Kilinç MA, Sari F, Ağin H. The first use of pralidoxime in a child with rivastigmine poisoning. <i>Pediatr Emerg Care</i>. 2018;34(10):e184-e186. doi:10.1097/PEC.0000000000001086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/28328690/pubmed" id="28328690" target="_blank">28328690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9776957">
<a name="9776957"></a>Schexnayder S, James LP, Kearns GL, et al. The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. <i>J Toxicol Clin Toxicol</i>. 1998;36(6):549-555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/9776957/pubmed" id="9776957" target="_blank">9776957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29667118">
<a name="29667118"></a>Stolbach A, Bebarta V, Beuhler M, et al. ACMT position statement: alternative or contingency countermeasures for acetylcholinesterase inhibiting agents. <i>J Med Toxicol</i>. 2018;14(3):261-263. doi:10.1007/s13181-018-0658-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/29667118/pubmed" id="29667118" target="_blank">29667118</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration. FDA alerts health care providers and emergency responders of expiration date extension updates for certain auto-injectors manufactured by Meridian Medical Technologies. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-providers-and-emergency-responders-expiration-date-extension-updates-certain" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-providers-and-emergency-responders-expiration-date-extension-updates-certain</a>. Updated July 12, 2021. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference">
                  Vale JA. Nerve Agents<i>.</i> In: Bateman DN, Jefferson RD, Thomas SHL, Thompson JP, Vale JA, eds.<i> Oxford Desk Reference Toxicology</i>. Oxford University Press; 2014:342-344.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27125761">
<a name="27125761"></a>Worek F, Thiermann H, Wille T. Oximes in organophosphate poisoning: 60 years of hope and despair. <i>Chem Biol Interact</i>. 2016;259(pt B):93-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/27125761/pubmed" id="27125761" target="_blank">27125761</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO) and United Nations Environment Programme (UNEP). Sound management of pesticides and diagnosis and treatment of pesticide poisoning: a resource tool. 2006. http://www.who.int/whopes/recommendations/IPCSPesticide_ok.pdf?ua=1
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 12720 Version 120.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
